Found 123 articles
Recce Pharmaceuticals Announces Positive Oral Data on New RECCE® 435 Against Helicobacter Pylori in Animal Model
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced positive efficacy activity against Helicobacter pylori bacteria in rats treated with new antibiotic RECCE® 435, including a favorable toxicity profile in a related study.
Recce Pharmaceuticals to Give Opening R&D Address at 2020 Virtual World Antibiotic Resistance Congress
Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Company ), the Company developing New Classes of Synthetic Anti-infectives, today announced that it will be delivering the Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress from the 8th – 9th October 2020. Due to the global pandemic, the conference will be held entirely virtually. The two-day World AMR Congress is the largest commercially focused conference with AMR at i
7/17/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE® Compounds in Expanded SARS-CoV-2 Program
Highlights: International study will be conducted in a laboratory at a leading academic institution in the U.S. to evaluate anti-viral activity of RECCE ® 327 and new antiviral formulation RECCE ® 529 Expanded program utilizing Centers for Disease Control (CDC) SARS-CoV-2 clinical isolate SARS-Related Coronavirus 2, Isolate USA-WA1/2020 Preliminary data anticipated September 2020 SYDNEY, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Compa
Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Company ), the Company developing new classes of synthetic anti-infectives, today announced the appointment of Alan W. Dunton, M.D., to its Board of Directors as an independent Non-Executive Director and as a member of the Company’s Audit & Risk and Remuneration & Nomination Committees. “On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors,” stated Dr. John Pre
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
Recce Pharmaceuticals Announces RECCE® Compounds Selected by CSIRO/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screening Program
Highlights: RECCE ® 327 and New RECCE ® 529 compounds were selected for their unique mechanisms of action against hyper-mutation, as indicated on bacteria and viruses (respectively) Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute Therapeutic antiviral treatment focus of RECCE ® 327 and RECCE ® 529 may see added potential benefit against secondary bacterial infections SYDNEY, Australia, July 08, 2020 (GLOBE NEWSWIRE)
Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of broad-spectrum synthetic antibiotics, today announced the completion of Dr. Graham Melrose’s executive service agreement as Chief Research Officer and his resignation as Executive Director from the Board. Dr. Melrose said: “Recce was formed with a mission to address the global health threat of antibiotic resistance and I feel we have made generationally s
Recce Pharmaceuticals Announces Positive Data on RECCE® 327 Against Neisseria gonorrhoeae in STD Animal Model
Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of broad-spectrum synthetic antibiotics, today announced positive efficacy showing significant antibacterial activity against Neisseria gonorrhoeae bacteria in mice treated with its lead compound RECCE® 327.
Recce Pharmaceuticals Announces First-Quarter 2020 Financial Results and Provides Operational Highlights
Recce Pharmaceuticals Ltd, the company developing a new class of broad-spectrum synthetic antibiotics, reported its March 2020 quarter results and operational highlights.
4/23/2020Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.
Recce Pharmaceuticals Announces More Positive Data on RECCE® 327 Against MRSA Superbug in Burn Wound Animal Model
Highlights: Statistically significant reduction in MRSA superbug bacterial load and higher percentage of wound contraction with RECCE ® 327 as compared to Soframycin in rat model for topical burns Study reinforces the potential of RECCE ® 327 against drug-resistant superbugs
Recce Pharmaceuticals Announces Positive Data on RECCE® 327 Against Influenza A Respiratory Virus Infection in Animal Model
Highlights: Dramatic reduction in viral load in the lungs of mice treated with RECCE ® 327 as compared to the approved antiviral drug treated and vehicle control untreated groups RECCE ® 327’s unique mechanism of action reinforces efficacy against both bacterial cells and enveloped viruses SYDNEY, Australia, April 20, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ), the company developing a new class of broad-spectrum synthetic antibiotics, today announced posit
4/13/2020It was a very busy week for clinical trial news. Here’s a look.
Recce Signs Phase I Clinical Trial Agreement to Initiate Study of Synthetic Antibiotic RECCE® 327 in Healthy Subjects
Highlights: Phase I trial agreement with leading clinical research organization Human safety and tolerability study to assess infusion of RECCE ® 327 in 40 healthy subjects as a single ascending dose Estimated start-to-completion with data read-outs less than 12 months from now First patients expected to be dosed in second half of 2020
Recce Pharmaceuticals Releases White Paper Providing Data and Market Positioning of its Synthetic Polymer Antibiotics
Recce Pharmaceuticals Ltd published a white paper providing pre-clinical and experimental data on its new synthetic antibiotics and outlining the market need, its anticipated market positioning and development strategy.
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share
This second patent family, titled ‘Copolymer for use in a method of treatment of a parenteral infection’, contains 13 claims and relates to methods of manufacture, administration and application to treat a broad range of common human infections, providing Recce intellectual property protection to November 2035
Recce Pharmaceuticals Ltd announced a successful grant application as one of five Industrial Partners in collaboration with 16 University and Public Health Organisations, to establish a National Anti-Microbial Resistant Research Hub in Sydney, Australia to combat antimicrobial resistance.